Immunological effects of interleukin-2 therapy in human immunodeficiency virus-positive subjects.
De Paoli
P
P
Microbiology, Immunology and Virology, Centro di Riferimento Oncologico, IRCCS, Aviano, Italy. pdepaoli@cro.it
D017209:Apoptosis / Q000276:immunology; D015551:Autoimmunity / Q000276:immunology; D018791:CD4 Lymphocyte Count; D016516:CD4-CD8 Ratio; D015496:CD4-Positive T-Lymphocytes / Q000166:cytology / Q000276:immunology; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D002455:Cell Division; D018925:Chemokines / Q000096:biosynthesis; D016207:Cytokines / Q000096:biosynthesis; D015488:HIV Antigens / Q000276:immunology; D015658:HIV Infections / Q000188:drug therapy / Q000276:immunology*; D006801:Humans; D007167:Immunotherapy; D007376:Interleukin-2 / Q000276:immunology* / Q000627:therapeutic use; D008221:Lymphoid Tissue / Q000276:immunology; D019707:Receptors, Chemokine / Q000096:biosynthesis; D013950:Thymus Gland / Q000276:immunology
D018925:Chemokines; D016207:Cytokines; D015488:HIV Antigens; D007376:Interleukin-2; D019707:Receptors, Chemokine